Photodynamic Therapy and Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration. A Randomized Clinical Trial

Ophthalmology

Volumn 116, Issue 11, 2009, Pages

  Maberley, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CIPROFLOXACIN; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR OPALESCENCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SIDE EFFECT; SUBCAPSULAR CATARACT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 70350574107     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.04.032     Document Type: Article

References (19)

1. Maberley D.A., Hollands H., Chuo J., et al. The prevalence of low vision and blindness in Canada. Eye 20 (2006) 341-346
2. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 109 (1991) 1242-1257
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
4. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
5. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
6. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
7. Schmidt-Erfurth U., and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45 (2000) 195-214
8. Schmidt-Erfurth U., Schlotzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived growth factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
9. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44 (2003) 2147-2154
10. Gollnick S.O., Evans S.S., Baumann H., et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88 (2003) 1772-1779
11. Schmidt-Erfurth U., Laqua H., Schlotzer-Schrehard U., et al. Histopathologic changes following photodynamic therapy in human eyes. Arch Ophthalmol 120 (2002) 835-844
12. Scholes G.N., O'Brien W.J., Abrams G.W., and Kubicek M.F. Clearance of triamcinolone from vitreous. Arch Ophthalmol 103 (1985) 1567-1569
13. Blumenkranz M.S., Claflin A., and Hajek A.S. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 102 (1984) 598-604
14. Ingber D., Madri J., and Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 119 (1986) 1768-1775
15. Chylack Jr. L.T., Leske M.C., McCarthy D., et al. Lens Opacities Classification System II (LOCS II). Arch Ophthalmol 107 (1989) 991-997
16. Tatar O., Shinoda K., Kaiserling E., et al. Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 126 (2008) 193-199
17. Ergun E., Maar N., Ansari-Shahrezaei S., et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 142 (2006) 10-16
18. Ruiz-Moreno J.M., Montero J.A., Barile S., and Zarbin M.A. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 26 (2006) 602-612
19. Arias L., Garcia-Arumi J., Ramon J.M., et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 113 (2006) 2243-2250